TrialAnnals of the rheumatic diseases2019

Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study.

Sudha Visvanathan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.